🔗 Share this article

As the United States proceeds with sweeping changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations during the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Agency leaders planned to unveil major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. This reveal has been delayed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US to become more similar to the Danish model, a society with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Background

Høeg has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of CBER would “understand legal statutes and the underlying principles of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who headed CBER have had.”

The drug center has an immense range of responsibilities at the agency, she stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and more, and every single one need to be supervised,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership element to the job, which oversees in excess of 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” Woodcock added.

Response and Disputed Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this appointment represents greater collaboration among agency officials on vaccines, a representative responded that the “inquiries are based on flawed presumptions”.

“Her experience is consistent with the responsibilities of her position,” the spokesperson said, noting the period Dr. Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed one-day drug-approval program that allegedly concerned her predecessors. “How are these medications being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of all drugs, except for immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard said. She authored a research paper using unverified volunteer-provided data to determine the frequency of myocarditis after Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the new administration featured altering regulations for recently developed shots and halting “non-essential” vaccines, she said after the election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who commences with her preconceived notions and tailors the evidence to accommodate the data in a highly disingenuous, fraudulent way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|